Accueil > Actualité
Actualite financiere : Actualite bourse

Merck: FDA grants priority review for Vaxneuvance

( - Merck today announced that the US FDA has agreed to give priority review to its supplemental Biologics License Application (sBLA) for Vaxneuvance to prevent invasive pneumococcal disease in children aged 6 weeks to 17 years.

Vaxneuvance has the potential to provide significant protection against invasive pneumococcal disease in children and infants by targeting pneumococcal strains, or serotypes, that contribute to a significant burden of disease, it said.

The FDA gives priority review to drugs and vaccines that, if approved, would significantly improve the safety or efficacy of the treatment or prevention of a serious disease.

Copyright (c) 2021 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.